SCHEMBL23532142

SCHEMBL23532142

CC(=O)c1c(F)cccc1OCC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.51
POLB P06746 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GLA P06280 1/20 0.51
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
KMT2A Q03164 1/20 0.48
PKM P14618 1/20 0.46
PTGDR2 Q9Y5Y4 3/20 0.45
FFAR1 O14842 2/20 0.43
CASP1 P29466 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
ALOX15 P16050 1/20 0.42
LMNA P02545 1/20 0.41
LTB4R Q15722 1/20 0.41
LTB4R2 Q9NPC1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8262562 0.83 KMT2A (0.50) L3MBTL1POLBGLAALDH1A1KMT2A
SCHEMBL24756346 0.83 KMT2A (0.44) L3MBTL1POLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL18702970 0.82 KDM4E (0.53) L3MBTL1POLBSMN1; SMN2GLAKDM4E
SCHEMBL3965332 0.82 MAOB (0.58) L3MBTL1POLBSMN1; SMN2GLAKDM4E
SCHEMBL20898918 0.82 L3MBTL1 (0.54) L3MBTL1POLBSMN1; SMN2GLAKDM4E
SCHEMBL23532093 0.81 DDB1 (0.43) POLBSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL23218373 0.81 KMT2A (0.57) L3MBTL1POLBSMN1; SMN2GLAKDM4E
SCHEMBL13602427 0.79 KMT2A (0.47) ALDH1A1KMT2ACES2CES1
SCHEMBL8261358 0.79 KMT2A (0.47) L3MBTL1POLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL29757370 0.79 L3MBTL1 (0.61) L3MBTL1POLBSMN1; SMN2GLAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159519-A1 NOVEL COMPOUNDS AND THEIR USE DEBIOPHARM INTERNATIONAL S.A. (CH) 2023-05-25 US disclosed
EP-4077324-A1 NOVEL COMPOUNDS AND THEIR USE Debiopharm International SA (CH) 2022-10-26 EP disclosed
WO-2021123372-A1 NOVEL COMPOUNDS AND THEIR USE DEBIOPHARM INTERNATIONAL S.A. (CH) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159519-A1 NOVEL COMPOUNDS AND THEIR USE LSS, PGLS, LDHB L3MBTL1 191/4885POLB 1161/4885SMN1; SMN2 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.